Oric Total Liab vs Cash And Short Term Investments Analysis

ORIC Stock

USD 9.59 0.47 5.15%

Oric Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oric Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oric Pharmaceuticals is a good investment. Please check the relationship between Oric Pharmaceuticals Total Liab and its Cash And Short Term Investments accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

Total Liab vs Cash And Short Term Investments

Total Liab vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oric Pharmaceuticals Total Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have pay attention.

The correlation between Oric Pharmaceuticals' Total Liab and Cash And Short Term Investments is -0.88. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Oric Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oric Pharmaceuticals' Total Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Oric Pharmaceuticals are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Liab i.e., Oric Pharmaceuticals' Total Liab and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.88

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Oric Pharmaceuticals balance sheet. This account contains Oric Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Oric Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Oric Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.The current year's Enterprise Value is expected to grow to about 581.3 M, whereas Selling General Administrative is forecasted to decline to about 17.5 M.

	2021	2022	2023	2024 (projected)
Interest Income	141K	2.6M	3.0M	3.2M
Net Interest Income	141K	2.6M	3.0M	3.2M

Interest Income Net Interest Income

Oric Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Other Current Liab		0.99	-0.94	0.88	-0.93	0.33	-0.02	0.89	0.99	0.19	0.91	0.92	0.61	-0.28	0.33	0.84	0.52	0.88	0.95	-0.88	0.96	0.86	0.97	-0.85	0.92	0.88
Total Current Liabilities	0.99		-0.89	0.88	-0.93	0.45	0.1	0.85	0.98	0.3	0.89	0.89	0.61	-0.29	0.34	0.89	0.58	0.85	0.96	-0.83	0.97	0.89	0.99	-0.79	0.89	0.93
Other Liab	-0.94	-0.89		-0.9	0.88	-0.25	0.24	-0.95	-0.93	0.1	-0.95	-0.98	-0.53	0.36	-0.4	-0.75	-0.53	-0.94	-0.84	0.96	-0.91	-0.83	-0.89	0.95	-0.98	-0.74
Net Tangible Assets	0.88	0.88	-0.9		-0.87	0.52	0.1	0.95	0.91	0.03	0.97	0.93	0.55	-0.31	0.36	0.77	0.49	0.96	0.75	-0.81	0.95	0.9	0.84	-0.77	0.93	0.75
Retained Earnings	-0.93	-0.93	0.88	-0.87		-0.35	-0.09	-0.79	-0.92	-0.33	-0.83	-0.83	-0.81	0.05	-0.11	-0.8	-0.41	-0.79	-0.93	0.8	-0.89	-0.8	-0.93	0.75	-0.83	-0.89
Accounts Payable	0.33	0.45	-0.25	0.52	-0.35		0.61	0.35	0.36	0.25	0.45	0.35	0.07	-0.52	0.54	0.71	0.69	0.38	0.34	-0.13	0.5	0.71	0.46	-0.09	0.35	0.57
Other Assets	-0.02	0.1	0.24	0.1	-0.09	0.61		-0.14	0.01	0.65	-0.07	-0.21	0.17	0.19	-0.18	0.23	0.08	-0.13	0.01	0.44	0.12	0.18	0.05	0.51	-0.21	0.3
Total Current Assets	0.89	0.85	-0.95	0.95	-0.79	0.35	-0.14		0.91	-0.17	0.99	0.99	0.38	-0.42	0.46	0.7	0.52	1.0	0.72	-0.9	0.93	0.85	0.81	-0.89	0.99	0.65
Common Stock	0.99	0.98	-0.93	0.91	-0.92	0.36	0.01	0.91		0.21	0.93	0.93	0.59	-0.23	0.28	0.8	0.51	0.91	0.91	-0.88	0.98	0.84	0.95	-0.84	0.93	0.87
Property Plant Equipment	0.19	0.3	0.1	0.03	-0.33	0.25	0.65	-0.17	0.21		-0.09	-0.14	0.49	0.51	-0.48	0.26	-0.02	-0.16	0.38	0.18	0.18	0.05	0.3	0.24	-0.14	0.52
Total Assets	0.91	0.89	-0.95	0.97	-0.83	0.45	-0.07	0.99	0.93	-0.09		0.99	0.44	-0.44	0.49	0.78	0.57	0.99	0.77	-0.89	0.96	0.9	0.86	-0.87	0.99	0.73
Total Stockholder Equity	0.92	0.89	-0.98	0.93	-0.83	0.35	-0.21	0.99	0.93	-0.14	0.99		0.43	-0.44	0.49	0.75	0.56	0.98	0.79	-0.95	0.93	0.86	0.86	-0.94	1.0	0.7
Property Plant And Equipment Net	0.61	0.61	-0.53	0.55	-0.81	0.07	0.17	0.38	0.59	0.49	0.44	0.43		0.37	-0.31	0.47	-0.12	0.41	0.71	-0.46	0.52	0.42	0.61	-0.4	0.43	0.61
Net Debt	-0.28	-0.29	0.36	-0.31	0.05	-0.52	0.19	-0.42	-0.23	0.51	-0.44	-0.44	0.37		-1.0	-0.53	-0.74	-0.4	-0.2	0.37	-0.32	-0.6	-0.31	0.39	-0.44	-0.21
Cash	0.33	0.34	-0.4	0.36	-0.11	0.54	-0.18	0.46	0.28	-0.48	0.49	0.49	-0.31	-1.0		0.58	0.75	0.44	0.25	-0.41	0.36	0.64	0.37	-0.43	0.49	0.26
Non Current Assets Total	0.84	0.89	-0.75	0.77	-0.8	0.71	0.23	0.7	0.8	0.26	0.78	0.75	0.47	-0.53	0.58		0.78	0.69	0.87	-0.66	0.84	0.95	0.92	-0.61	0.75	0.92
Non Currrent Assets Other	0.52	0.58	-0.53	0.49	-0.41	0.69	0.08	0.52	0.51	-0.02	0.57	0.56	-0.12	-0.74	0.75	0.78		0.5	0.51	-0.48	0.58	0.74	0.64	-0.47	0.56	0.65
Cash And Short Term Investments	0.88	0.85	-0.94	0.96	-0.79	0.38	-0.13	1.0	0.91	-0.16	0.99	0.98	0.41	-0.4	0.44	0.69	0.5		0.71	-0.9	0.93	0.85	0.8	-0.88	0.98	0.65
Common Stock Shares Outstanding	0.95	0.96	-0.84	0.75	-0.93	0.34	0.01	0.72	0.91	0.38	0.77	0.79	0.71	-0.2	0.25	0.87	0.51	0.71		-0.8	0.86	0.79	0.98	-0.76	0.79	0.93
Non Current Liabilities Total	-0.88	-0.83	0.96	-0.81	0.8	-0.13	0.44	-0.9	-0.88	0.18	-0.89	-0.95	-0.46	0.37	-0.41	-0.66	-0.48	-0.9	-0.8		-0.82	-0.73	-0.83	1.0	-0.95	-0.64
Capital Surpluse	0.96	0.97	-0.91	0.95	-0.89	0.5	0.12	0.93	0.98	0.18	0.96	0.93	0.52	-0.32	0.36	0.84	0.58	0.93	0.86	-0.82		0.9	0.93	-0.79	0.93	0.86
Other Current Assets	0.86	0.89	-0.83	0.9	-0.8	0.71	0.18	0.85	0.84	0.05	0.9	0.86	0.42	-0.6	0.64	0.95	0.74	0.85	0.79	-0.73	0.9		0.88	-0.7	0.86	0.83
Other Stockholder Equity	0.97	0.99	-0.89	0.84	-0.93	0.46	0.05	0.81	0.95	0.3	0.86	0.86	0.61	-0.31	0.37	0.92	0.64	0.8	0.98	-0.83	0.93	0.88		-0.79	0.86	0.95
Total Liab	-0.85	-0.79	0.95	-0.77	0.75	-0.09	0.51	-0.89	-0.84	0.24	-0.87	-0.94	-0.4	0.39	-0.43	-0.61	-0.47	-0.88	-0.76	1.0	-0.79	-0.7	-0.79		-0.94	-0.58
Net Invested Capital	0.92	0.89	-0.98	0.93	-0.83	0.35	-0.21	0.99	0.93	-0.14	0.99	1.0	0.43	-0.44	0.49	0.75	0.56	0.98	0.79	-0.95	0.93	0.86	0.86	-0.94		0.7
Property Plant And Equipment Gross	0.88	0.93	-0.74	0.75	-0.89	0.57	0.3	0.65	0.87	0.52	0.73	0.7	0.61	-0.21	0.26	0.92	0.65	0.65	0.93	-0.64	0.86	0.83	0.95	-0.58	0.7

Click cells to compare fundamentals

Oric Pharmaceuticals Account Relationship Matchups

Oric Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	5.2M	8.2M	11.3M	11.4M	16.8M	8.7M
Total Current Liabilities	5.4M	9.0M	15.2M	15.4M	20.5M	11.1M
Net Tangible Assets	(90.1M)	289.8M	273.0M	222.4M	255.7M	268.5M
Retained Earnings	(92.7M)	(166.4M)	(245.1M)	(334.2M)	(434.9M)	(413.2M)
Accounts Payable	152K	757K	1.9M	1.3M	944K	1.0M
Other Assets	0.0	319K	521K	517K	594.6K	433.8K
Total Current Assets	90.0M	296.7M	240.5M	210.5M	212.6M	176.1M
Property Plant Equipment	2.2M	2.0M	2.4M	3.3M	3.7M	2.8M
Total Assets	94.1M	299.0M	298.6M	247.2M	252.0M	226.9M
Total Stockholder Equity	88.0M	289.8M	273.0M	222.4M	224.1M	189.3M
Property Plant And Equipment Net	2.2M	2.0M	2.4M	3.3M	12.0M	12.6M
Net Debt	(89.2M)	(78.4M)	(224.1M)	(64.2M)	(13.2M)	(13.8M)
Cash	89.2M	78.4M	226.0M	66.8M	23.4M	22.2M
Non Current Assets Total	4.1M	2.3M	58.1M	36.7M	39.4M	26.3M
Non Currrent Assets Other	1.9M	319K	12.3M	11.5M	552K	524.4K
Cash And Short Term Investments	89.2M	293.6M	237.0M	206.3M	208.2M	197.4M
Common Stock Shares Outstanding	29.9M	21.9M	38.0M	39.7M	51.5M	36.7M
Liabilities And Stockholders Equity	94.1M	299.0M	298.6M	247.2M	252.0M	226.9M
Non Current Liabilities Total	765K	219K	10.5M	9.4M	7.5M	7.1M
Capital Surpluse	2.6M	456.2M	518.2M	557.9M	641.5M	338.0M
Other Current Assets	840K	3.1M	7.1M	4.2M	4.4M	3.8M
Other Stockholder Equity	180.7M	157.2M	518.2M	557.9M	658.8M	380.7M
Total Liab	6.1M	9.2M	25.7M	24.8M	27.9M	27.3M
Net Invested Capital	88.0M	289.8M	273.0M	222.4M	224.1M	189.3M
Property Plant And Equipment Gross	2.2M	2.0M	7.4M	9.0M	9.4M	6.0M
Accumulated Other Comprehensive Income	(178.1M)	(31K)	(103K)	(1.3M)	258K	270.9K
Net Working Capital	84.6M	287.7M	225.4M	195.1M	192.1M	188.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:

How To Invest In Oric

Details

Is Oric Stock a good investment?

Details

What is Oric Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Return On Assets

(0.29)

Return On Equity

(0.46)

The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oric Total Liab vs Cash And Short Term Investments Analysis

Total Liab vs Cash And Short Term Investments

Total Liab vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Total Liab

Cash And Short Term Investments

Oric Pharmaceuticals fundamental ratios Correlations

Oric Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oric Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Total Current Liabilities	+ 0.99	Other Current Liab
Common Stock	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Invested Capital	- 0.98	Other Liab
Total Stockholder Equity	- 0.98	Other Liab
Net Invested Capital	- 0.95	Non Current Liabilities Total
Non Current Liabilities Total	- 0.95	Total Stockholder Equity
Total Assets	- 0.95	Other Liab